Company Clarifies Cash Situation And Prospects.

GAITHERSBURG, Md.--(BUSINESS WIRE)--March 27, 1998--Oncor, Inc. (AMEX:ONC) has been informed that whenever an entity maintains assured cash reserves no greater than twelve months of cash losses, at current rates of loss, it will receive a "going concern" report, including the "substantial doubt" language prescribed by the AICPA, from its independent accountants. The company's cash reserves have not exceeded twelve months of its historical cash losses and as previously reported, the company received such a report for the year ended Dec. 31, 1997.

Management emphasizes again that it fully expects to continue in existence for the foreseeable future. The company is considering several alternative sources of cash, which were not assured at the time of the issuance of the accountant's report, but management believes will become assured, to a sufficient extent, in the next few weeks. These sources include equity financing, sale of significant assets, strategic alternatives, sale of the company's holdings in publicly-traded OncorMed and recovery of company advances for Codon. More than one of these potential transactions is in an advanced stage.

In addition, management has taken severe steps to reduce the level of ongoing operating expenditures substantially and continues to have confidence in the sales potential for its recently approved INFORM(TM) HER-2/neu breast cancer diagnostic test. The combination of these activities is expected to have a strong favorable effect on the cash flow of the company in the next year. While there can be no assurance that management's actions and the aforementioned cash sources will be sufficient, management remains confident in the financial viability for the company.

The company also continues to believe that its efforts, in conjunction with those its financial advisors -- Lehman Brothers -- to effect a significant strategic transaction, including possible sale of the company, remain of paramount importance.

Oncor, Inc. (http://www.oncor.com) develops, manufactures and markets gene-based test systems and related products for use in the detection and management of cancer and other human disease.

This press release contains statements of a forward-looking nature regarding future events. These statements are only predictions and actual events may differ materially. Please refer to documents that Oncor files from time to time with the Securities and Exchange Commission for a discussion of certain factors that could cause actual results to differ materially from those contained in the forward-looking statements.

CONTACT: Jose Coronas, Acting Chief Executive Officer

Cecil Kost, Chief Operating Officer 

John Coker, Chief Financial Officer

[phone]

[e-mail]